Medtronic

MDT

Market cap $102B

Medtronic (MDT) reached $83.87 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

I initiate coverage on Medtronic, highlighting its status as a leading medtech name with premium margins. MDT offers an attractive diversification opportunity, combining consistent performance with accelerated revenue growth. The stock trades at undervalued levels, supporting a long-term bullish thesis and a defensive investment approach.

Medtronic plc is rated buy with a $92 price target, reflecting conservative fiscal 2027 guidance and resilient growth platforms. Fiscal 2026 delivered $36.4B in revenue, the strongest growth in a decade, led by Cardiovascular and ablation solutions outpacing market rates. Guidance for fiscal 2027 excludes potential catalysts—MiniMed separation, tariff refunds, and Blackstone payment relief—implying room for upside surprises.

Medtronic is a dividend aristocrat with a near-decade high yield, making it an attractive long-term income opportunity. The company is experiencing strong revenue growth, driven by its leading positions in cardiovascular and neuroscience medical devices. While current free cash flow payout ratios are sustainable, investors should monitor future dividend growth rates closely.

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic (MDT) reached $78.23 at the closing of the latest trading day, reflecting a -3.34% change compared to its last close.

Globus Medical or Medtronic? See why Globus Medical's stronger growth, innovation and analyst upside may give it the edge despite a richer valuation.

Dividend Aristocrats rebounded in June and are now outperforming SPY YTD with a 9.61% return versus SPY's 6.91%. CAT leads 2026 performance at +76.98%, with 46 Aristocrats now ahead of SPY and 39 posting double-digit total returns. Recent dividend increases averaged 4.09%, slightly below the 2025 average, with 2026's average dividend growth rate at 3.97%.

These healthcare leaders have encountered challenges in recent years. However, they are slowly improving their businesses, partly through innovation.